Abstract
Chronic hepatitis B virus infection is a common disease afflicting 300 million people worldwide, including approximately one million Americans who are carriers of the hepatitis B surface antigen (HBSAg). Many such carriers have concomitant chronic liver disease and are at risk for developing cirrhosis, liver failure and hepatocellular carcinoma (1, 2). Impaired effectiveness of the host cellular immune mechanisms in clearing hepatitis B virus (HBV) infected hepatocytes has been proposed to explain development of chronic HBV infection (3, 4).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Seeff LB, Koff RS: Evolving concepts of the clinical and serologic consequences of hepatitis B virus infection. Sem Liver Dis 6:11–22, 1986
Hoofnagle JH, Alter HJ. Chronic viral hepatitis. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York: Grune & Stratton, 97–113, 1984
Thomas HC, Lever AML, Scully LJ, Pignatelli M: Approaches to the treatment of hepatitis B virus and Delta-related liver disease. Sem Liver Dis 6:34–41, 1986
Dienstag JL: Immunologic mechanisms in chronic viral hepatitis. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York: Grune & Stratton, 135–66, 1984
Alexander GJM, Williams R: Natural history and therapy of chronic hepatitis B virus infection. Am J Med 85:143–146, 1988
DiBisceglie AM, Hoofnagle JH: Antiviral therapy of chronic viral hepatitis. Am J Gastro 85:650–654, 1990
Lever AML: Treatment of the chronic hepatitis B virus carrier state. J Infect 16:221–229, 1988
Aach, RD: The treatment of chronic type B viral hepatitis. Ann Int Med 109:89–91, 1988
Perrillo RP, Regenstein FG, Peters MG, et al: Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. Ann Int Med 109:95–100, 1988
Hoofnagle JH, Peters M, Mullen KD, et al: Randomized, controlled trial of recombinant human a-interferon in patients with chronic hepatitis B. Gastroenterology 95:1318–1325, 1988
Perrillo RP, Schiff ER, Davis GL, et al: A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Eng J Med 323:295–301, 1990
Renault PF, Hoofnagle JH, Park Y, et al: Psychiatric complications of long-term interferon alfa (sic) therapy. Arch Intern Med 147:1577–1580, 1987
Low TLK, Goldstein AL: Thymosins: structure, function and therapeutic applications. Thymus 6:27–42, 1984
Goldstein AL, Guha A, Zatz MM, et al: Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci USA 69:1800–1803, 1972
Wetzel R, Heyneker HL, Goeddel DV, et al: Production of biologically active Nα-desacetyl thymosin αl in E. coli through expression of a chemically synthesized gene. Biochem 19:6096–6104, 1980
Low TLK, Thurman GB, McAdoo M, et al: I. Isolation, characterization and biological activities of thymosin al and polypeptide α1 from calf thymus. J Biol Chem 254:981–86, 1979
Marshall GD, Thurman GB, Rossio JL, Goldstein AL: In vivo generation of suppressor T-cells by thymosin in congenitally athymic nude mice. J Immunol 126:741–44, 1981
Mutchnick MG, Prieto JA, Schaffner JA, Weller FE. Thymosin modulation of regulatory T cell function. Clin Immunol Immuno 23:626–33, 1982
Sztein MB, Serrate SA, Goldstein AL: Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci USA 83:6107–6111, 1986
Serrate SA, Schulof RS, Leondaridis L, et al: Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol 139:2338–2343, 1987
Favalli C, Jezzi T, Mastino A, et al: Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother 20:189–192, 1985
Baxevanis CN, Reclos GJ, Perez S, et al: Immunoregulatory effects of fraction 5 thymus peptides. I. Thymosin enhances while thymosin B4 suppresses the human autologous and allogeneic mixed lymphocyte reaction. Immunopharm 13:133–141, 1987
Svedersky LP, Hui A, May L, et al: Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by N alpha - desacetylthmosin αl. J Immunol 12:244–247, 1982
Sztein MB, Goldstein AL: Thymic hormones-a clinical update. Springer Sem Immunopathol 9:1–18, 1986
Mutchnick MG, Missirian A, Johnson AG: Lymphocyte cytotoxicity in human liver disease using rat hepatocyte monolayer cultures. Clin Immunol Immunopathol 16:423–437, 1980
Mutchnick MG, Schaffner JA, Prieto JA, et al: Increased thymic hormone responsive suppressor T lymphocyte function in chronic active hepatitis. Dig Dis Sci 28:328–334, 1983
Shen S, Josselson J, McRoy C, et al: Effects of thymosin alpha-1 (TA-1) on peripheral T-cell and Heptavax-B vaccination (V) in previously non-responsive hemodialysis (HD) patients (Pts). Hepatology 7:1120, 1987
Mutchnick MG, Appelman HD, Chung HT, et al: Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hepatology (in press).
Knodell RG, Ishak KG, Black WC, et al: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–35, 1981
Mutchnick MG, Lee HH, Hollander DI, et al: Defective in vitro gamma interferon production and elevated serum immunoreactive thymosin β4 levels in patients with inflammatory bowel disease. Clin Immunol Immunopathol 47:84–92, 1988
Shafritz DA, Shouval D, Sherman HI, et al: Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. N Engl J Med 305:1067–1073, 1981
Zav’yalov VP, Denesyuk AI, Zav’yalova GA: Theoretical analysis of conformation and active sites of interferons. Immunol Lett 22:173–181, 1989
Korba BE, Tennant BC, Cote PJ, Mutchnick M, Gerin JL: Treatment of chronic woodchuck hepatitis virus infection with thymosin alpha-1. Hepatology 12:880, 1990
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Mutchnick, M.G., Cummings, G.D., Hoofnagle, J.H., Shafritz, D.A. (1992). Thymosin: An Innovative Approach to the Treatment of Chronic Hepatitis B. In: Goldstein, A.L., Garaci, E. (eds) Combination Therapies. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3340-5_18
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3340-5_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6472-6
Online ISBN: 978-1-4615-3340-5
eBook Packages: Springer Book Archive